Research programme: LG914 inhibitors - Amgen/Lexicon Genetics

Drug Profile

Research programme: LG914 inhibitors - Amgen/Lexicon Genetics

Alternative Names: LG914 inhibitors research programme - Abgenix/Lexicon Genetics

Latest Information Update: 02 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen; Lexicon Genetics
  • Developer Amgen; Lexicon Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 02 May 2007 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 07 Sep 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top